Wordt geladen...
The BRAF(V600E) mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
OBJECTIVES: Preclinical studies showed that BRAF(V600E) mutation significantly reduced radioiodine uptake and decreased the sensitivity to radioactive iodine (RAI) therapy. However, clinical data regarding its role in therapeutic decision making with respect to RAI therapy are currently insufficient...
Bewaard in:
| Gepubliceerd in: | Nucl Med Commun |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Lippincott Williams & Wilkins
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282664/ https://ncbi.nlm.nih.gov/pubmed/30312216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MNM.0000000000000930 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|